The stock of Immunomedics, Inc. (NASDAQ:IMMU) is a huge mover today! About 5.42M shares traded hands or 163.11% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has declined 9.60% since March 29, 2016 and is downtrending. It has underperformed by 13.07% the S&P500.
The move comes after 8 months positive chart setup for the $259.93M company. It was reported on Oct, 31 by Barchart.com. We have $6.12 PT which if reached, will make NASDAQ:IMMU worth $408.09 million more.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Out of 2 analysts covering Immunomedics (NASDAQ:IMMU), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Immunomedics has been the topic of 6 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The company was maintained on Tuesday, March 15 by Jefferies. Jefferies reinitiated the stock with “Buy” rating in Thursday, October 6 report. Wells Fargo downgraded the stock to “Market Perform” rating in Tuesday, June 21 report. As per Wednesday, July 29, the company rating was downgraded by Jefferies. The rating was upgraded by Jefferies on Friday, May 6 to “Buy”.
According to Zacks Investment Research, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.09, from 1.11 in 2016Q1. The ratio turned negative, as 14 funds sold all Immunomedics, Inc. shares owned while 34 reduced positions. 27 funds bought stakes while 22 increased positions. They now own 50.90 million shares or 5.47% more from 48.26 million shares in 2016Q1.
Teachers Advsr accumulated 0% or 170,514 shares. Parametric Port Assoc Limited Liability Company holds 0% or 25,855 shares in its portfolio. Moreover, Sphera Funds Limited has 0.24% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 400,000 shares. Geneva Advisors Limited Co has 0% invested in the company for 33,935 shares. Cambridge Invest Research Advsrs Inc has 0% invested in the company for 10,800 shares. Hightower Advsrs Ltd accumulated 53,865 shares or 0% of the stock. Creative Planning accumulated 58,485 shares or 0% of the stock. Bridgeway Cap Mgmt Incorporated has 0.01% invested in the company for 288,900 shares. Jefferies Grp Ltd Llc reported 37,800 shares or 0% of all its holdings. Jpmorgan Chase last reported 794 shares in the company. Price T Rowe Associates Md, a Maryland-based fund reported 33,100 shares. Stephens Inc Ar holds 0% or 10,000 shares in its portfolio. Millennium Limited Liability holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 259,762 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 3,396 shares. Swiss State Bank reported 145,450 shares or 0% of all its holdings.
Insider Transactions: Since June 6, 2016, the stock had 0 buys, and 7 sales for $5.11 million net activity. Another trade for 15,000 shares valued at $44,673 was sold by PAETZOLD MARY E. $29,451 worth of Immunomedics, Inc. (NASDAQ:IMMU) was sold by Stark Don C on Wednesday, August 24. $1.37M worth of Immunomedics, Inc. (NASDAQ:IMMU) was sold by GOLDENBERG CYNTHIA L. GOLDENBERG DAVID M sold $1.13M worth of stock or 371,990 shares. 15,000 shares were sold by MARKISON BRIAN A, worth $44,634 on Tuesday, August 23.
Another recent and important Immunomedics, Inc. (NASDAQ:IMMU) news was published by 247Wallst.com which published an article titled: “Immunomedics Falls Sharply on Secondary Offering” on October 05, 2016.
IMMU Company Profile
Immunomedics, Inc., incorporated on July 6, 1982, is a clinical-stage biopharmaceutical company, which is engaged in researching, developing, manufacturing and marketing biopharmaceutical products. It develops monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s geographic divisions include United States and Europe. The Company’s technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. As of June 30, 2016, the Company had a pipeline of eight clinical-stage product candidates. The Company’s portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while managing the overall toxic effects that are found with conventional administration of these chemotherapy agents. The Company, as part of a research collaboration, is focused on studying epratuzumab as a thorium-227-labeled antibody. The Firm also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development. These include combination therapies involving antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its DOCK-AND-LOCK (DNL) protein conjugation technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.